(CTKB) Cytek Biosciences - Ratings and Ratios
Cell Analyzers, Flow Cytometers, Reagents, Software, Sorter
CTKB EPS (Earnings per Share)
CTKB Revenue
Description: CTKB Cytek Biosciences
Cytek Biosciences Inc (NASDAQ:CTKB) is a cell analysis solutions company that provides innovative tools for biomedical research and clinical applications. The companys product portfolio includes a range of cell analysis systems, such as the Aurora and Northern Lights systems, which leverage full-spectrum profiling technology to expand potential applications in cell analysis.
The companys products cater to a diverse customer base, including pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. Cytek Biosciences has a global presence, with a direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions, as well as distributors and sales agents in other regions.
To evaluate the companys performance, some key performance indicators (KPIs) to consider are revenue growth, gross margin, and research and development (R&D) expenses as a percentage of revenue. Given the companys negative return on equity (RoE) of -2.90%, it is essential to analyze the companys cash flow management and burn rate to ensure it has sufficient resources to fund its operations and drive growth.
From a valuation perspective, the companys price-to-sales (P/S) ratio and enterprise value-to-EBITDA (EV/EBITDA) ratio can provide insights into its relative valuation compared to industry peers. Additionally, analyzing the companys customer acquisition costs and retention rates can help assess its sales and marketing efficiency.
To further assess the companys prospects, it is crucial to monitor its product pipeline, regulatory approvals, and competitive landscape. The companys ability to expand its product offerings and maintain its market share in the cell analysis solutions market will be critical to its long-term success.
CTKB Stock Overview
| Market Cap in USD | 511m |
| Sub-Industry | Health Care Equipment |
| IPO / Inception | 2021-07-23 |
CTKB Stock Ratings
| Growth Rating | -80.5% |
| Fundamental | 41.9% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -38.1% |
| Analyst Rating | 3.33 of 5 |
CTKB Dividends
Currently no dividends paidCTKB Growth Ratios
| Growth Correlation 3m | 78.4% |
| Growth Correlation 12m | -73.6% |
| Growth Correlation 5y | -93.2% |
| CAGR 5y | -33.05% |
| CAGR/Max DD 3y | -0.39 |
| CAGR/Mean DD 3y | -0.56 |
| Sharpe Ratio 12m | -0.82 |
| Alpha | 0.00 |
| Beta | 0.478 |
| Volatility | 64.22% |
| Current Volume | 926.6k |
| Average Volume 20d | 804.7k |
| Stop Loss | 3.6 (-8.2%) |
| Signal | -0.59 |
Piotroski VR‑10 (Strict, 0-10) 3.0
| Net Income (-6.40m TTM) > 0 and > 6% of Revenue (6% = 11.8m TTM) |
| FCFTA 0.02 (>2.0%) and ΔFCFTA 0.04pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 157.9% (prev 167.8%; Δ -9.87pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.03 (>3.0%) and CFO 15.2m > Net Income -6.40m (YES >=105%, WARN >=100%) |
| Net Debt (-61.4m) to EBITDA (2.11m) ratio: -29.08 <= 3.0 (WARN <= 3.5) |
| Current Ratio 5.22 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (126.9m) change vs 12m ago -3.43% (target <= -2.0% for YES) |
| Gross Margin 54.42% (prev 54.97%; Δ -0.55pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 40.13% (prev 40.87%; Δ -0.74pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -4.17 (EBITDA TTM 2.11m / Interest Expense TTM 1.52m) >= 6 (WARN >= 3) |
Altman Z'' 3.21
| (A) 0.63 = (Total Current Assets 382.8m - Total Current Liabilities 73.3m) / Total Assets 493.3m |
| (B) -0.11 = Retained Earnings (Balance) -52.2m / Total Assets 493.3m |
| (C) -0.01 = EBIT TTM -6.32m / Avg Total Assets 488.5m |
| (D) -0.45 = Book Value of Equity -52.1m / Total Liabilities 115.8m |
| Total Rating: 3.21 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 41.90
| 1. Piotroski 3.0pt = -2.0 |
| 2. FCF Yield 4.33% = 2.16 |
| 3. FCF Margin 5.64% = 1.41 |
| 4. Debt/Equity 0.02 = 2.50 |
| 5. Debt/Ebitda 2.95 = -1.70 |
| 6. ROIC - WACC (= -9.37)% = -11.72 |
| 7. RoE -1.66% = -0.28 |
| 8. Rev. Trend 26.66% = 2.00 |
| 9. EPS Trend -9.63% = -0.48 |
What is the price of CTKB shares?
Over the past week, the price has changed by +4.81%, over one month by -3.45%, over three months by +22.88% and over the past year by -26.59%.
Is Cytek Biosciences a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CTKB is around 3.00 USD . This means that CTKB is currently overvalued and has a potential downside of -23.47%.
Is CTKB a buy, sell or hold?
- Strong Buy: 1
- Buy: 1
- Hold: 3
- Sell: 1
- Strong Sell: 0
What are the forecasts/targets for the CTKB price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 5.1 | 30.9% |
| Analysts Target Price | 5.1 | 30.9% |
| ValueRay Target Price | 3.3 | -15.3% |
Last update: 2025-09-04 04:35
CTKB Fundamental Data Overview
CCE Cash And Equivalents = 262.0m USD (Cash And Short Term Investments, last quarter)
P/E Forward = 370.3704
P/S = 2.6089
P/B = 1.3546
Beta = 1.345
Revenue TTM = 196.0m USD
EBIT TTM = -6.32m USD
EBITDA TTM = 2.11m USD
Long Term Debt = 791.0k USD (from longTermDebt, last quarter)
Short Term Debt = 5.44m USD (from shortLongTermDebt, last quarter)
Debt = 6.24m USD (Calculated: Short Term 5.44m + Long Term 791.0k)
Net Debt = -61.4m USD (from netDebt column, last quarter)
Enterprise Value = 255.7m USD (511.4m + Debt 6.24m - CCE 262.0m)
Interest Coverage Ratio = -4.17 (Ebit TTM -6.32m / Interest Expense TTM 1.52m)
FCF Yield = 4.33% (FCF TTM 11.1m / Enterprise Value 255.7m)
FCF Margin = 5.64% (FCF TTM 11.1m / Revenue TTM 196.0m)
Net Margin = -3.27% (Net Income TTM -6.40m / Revenue TTM 196.0m)
Gross Margin = 54.42% ((Revenue TTM 196.0m - Cost of Revenue TTM 89.4m) / Revenue TTM)
Tobins Q-Ratio = -4.91 (set to none) (Enterprise Value 255.7m / Book Value Of Equity -52.1m)
Interest Expense / Debt = 6.64% (Interest Expense 414.0k / Debt 6.24m)
Taxrate = 21.0% (US default)
NOPAT = -6.32m (EBIT -6.32m, no tax applied on loss)
Current Ratio = 5.22 (Total Current Assets 382.8m / Total Current Liabilities 73.3m)
Debt / Equity = 0.02 (Debt 6.24m / last Quarter total Stockholder Equity 377.6m)
Debt / EBITDA = 2.95 (Net Debt -61.4m / EBITDA 2.11m)
Debt / FCF = 0.56 (Debt 6.24m / FCF TTM 11.1m)
Total Stockholder Equity = 384.6m (last 4 quarters mean)
RoA = -1.30% (Net Income -6.40m, Total Assets 493.3m )
RoE = -1.66% (Net Income TTM -6.40m / Total Stockholder Equity 384.6m)
RoCE = -1.64% (Ebit -6.32m / (Equity 384.6m + L.T.Debt 791.0k))
RoIC = -1.62% (NOPAT -6.32m / Invested Capital 389.6m)
WACC = 7.75% (E(511.4m)/V(517.7m) * Re(7.78%)) + (D(6.24m)/V(517.7m) * Rd(6.64%) * (1-Tc(0.21)))
Shares Correlation 3-Years: -72.73 | Cagr: -0.80%
Discount Rate = 7.78% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 70.46% ; FCFE base≈10.9m ; Y1≈7.16m ; Y5≈3.27m
Fair Price DCF = 0.51 (DCF Value 64.3m / Shares Outstanding 127.2m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: -9.63 | EPS CAGR: -31.21% | SUE: 0.0 | # QB: 0
Revenue Correlation: 26.66 | Revenue CAGR: 4.43% | SUE: -0.27 | # QB: 0
Additional Sources for CTKB Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle